Therapeutic strategies directly targeting proinflammatory cytokines [e.g. tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β) neutralization, methotrexate and colchicine] have shown great promise in experimental and clinical studies in atherosclerosis [35–41]. The gene discussed is TNF; the disease is atherosclerosis.